Vertex Pharmaceuticals Executive Vice President Ourania Tatsis sold a total of 1,887 shares of common stock in two transactions executed under a Rule 10b5-1 trading plan, according to a Form 4 filed with the Securities and Exchange Commission.
The filings show Tatsis sold 260 shares on February 25, 2026 at $486.35 per share, generating $126,451. On the prior trading day, February 24, she sold 1,627 shares at $485.11 per share for $789,273. Both sales were executed under a trading plan that Tatsis established on August 21, 2025. After these dispositions, Tatsis directly holds 46,763 shares of the company.
These insider transactions come as Vertex shares are trading close to their 52-week high of $519.68 and have returned 23.4% over the past six months. The company carries a market value of $121.85 billion and trades at a price-to-earnings ratio of 31.29. An InvestingPro analysis notes the stock appears overvalued relative to its Fair Value.
Vertex also recently reported fourth-quarter 2025 results. Revenue came in at $3.19 billion, narrowly above the $3.18 billion consensus. Earnings per share were $5.03, slightly missing the expected $5.08.
Despite the EPS miss, several analysts have responded positively to Vertex’s outlook. Cantor Fitzgerald raised its price target to $590, citing the potential for the company’s renal franchise to reach a scale comparable to its cystic fibrosis business. Oppenheimer upgraded Vertex from Perform to Outperform and set a $540 price target, driven by optimism around renal pipeline candidates povetacicept and inaxaplin.
Context and implications
The sales were conducted under an established Rule 10b5-1 plan and disclosed via a Form 4 filing, which are standard mechanisms for preplanned insider trades. The market reaction and valuation commentary noted here reflect current price action and published analyst assessments, including InvestingPro’s Fair Value view and recent analyst price-target revisions.